A convergence of market forces will push life sciences employers to rethink their workforce strategies and reimagine how work gets done, writes Ruby van den Hoff.

In the AI era, thriving life sciences organizations will differentiate themselves based on their ability to combine AIs power with distinctly human capabilities, writes Christine Ann Miller.

The Business of Biotech was back in San Francisco for JPM in January, and offers here a few observations, highlights, and ...

Congress finally reauthorized the Rare Pediatric Disease Priority Review Voucher program, after it expired in 2024. That matters a lot to patients and drug developers, writes George Magrath, M.D.

There is more than one way to blockbuster product sales, and sometimes smaller might be better, writes Bennett Smith.

On this week's episode of the Business of Biotech, Brian Hilberdink, President of U.S. Human Pharma at Boehringer Ingelheim, returns to the show during the J.P. Morgan Healthcare Conference, following ...

Biotechnology is all about scientific breakthroughs that lead to transformative therapies. But despite billions invested and years of R&D, data from Deloitte found that more than half of drug launches ...

“THAT WAS A TERRIFYING MOMENT,” reflects Matt Patterson, cofounder, chairman, and CEO of Audentes Therapeutics, a genetic medicines company focused on the adeno-associated virus (AAV). It was the fall ...

In a complex global and competitive world, formulating a plan without testing it against likely external reactions is the equivalent of walking into a battlefield without the right weapons or a plan ...

A revolution is coming in the U.S. generics marketplace, one that players in the space ignore at their peril. This revolution has the potential to transform savvy organizations into engines of growth, ...

Why did John Oyler, an American entrepreneur, decide to build a global biopharmaceutical company with roots in China? Ask the chairman, cofounder, and CEO of BeiGene that question and you’re going to ...

The False Claims Act (FCA) and the Anti-Kickback Statute (AKS) are two of the Department of Justice’s (DOJ) primary tools when it comes to fighting fraud. Originally enacted during the Civil War to ...